TABLE 2.
Susceptibility profiles of Enterobacteriaceae isolates collected from hospitalized patients with pneumonia in U.S. hospitals
| Organism or organism group (no. tested) | % susceptibility using CLSI interpretative criteria |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ceftolozane-tazobactam | Ceftazidime | Cefepime | Meropenem | Piperacillin-tazobactam | Amikacin | Colistina | Levofloxacin | Tigecyclineb | |
| Enterobacteriaceae (2,362) | 90.6 | 84.0 | 88.2 | 95.6 | 86.1 | 98.0 | 75.1 | 84.2 | 98.5 |
| Escherichia coli (441) | 98.0 | 85.9 | 85.0 | 99.8 | 90.4 | 99.5 | 99.5 | 60.2 | 100.0 |
| Klebsiella pneumoniae (627) | 85.8 | 77.5 | 78.6 | 88.7 | 81.7 | 93.8 | 96.8 | 82.5 | 99.0 |
| Klebsiella oxytoca (190) | 97.4 | 97.4 | 97.4 | 98.9 | 88.9 | 100.0 | 100.0 | 98.9 | 100.0 |
| Enterobacter cloacae (270) | 83.3 | 74.4 | 90.0 | 98.9 | 81.0 | 99.6 | 79.6 | 96.3 | 99.6 |
| Enterobacter aerogenes (161) | 90.1 | 78.9 | 98.1 | 98.8 | 81.2 | 99.4 | 96.3 | 97.5 | 99.4 |
| Citrobacter koseri (42) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 92.9 | 100.0 |
| Citrobacter freundii (32) | 68.8 | 62.5 | 87.5 | 96.9 | 71.9 | 100.0 | 96.9 | 96.9 | 100.0 |
| Proteus mirabilis (90) | 98.9 | 98.9 | 96.7 | 98.9 | 100.0 | 100.0 | 0.0 | 67.8 | 75.6 |
| Indole-positive Proteeae (46) | 95.7 | 89.1 | 93.5 | 100.0 | 97.8 | 100.0 | 0.0 | 69.6 | 93.5 |
| Serratia spp. (354) | 94.4 | 95.2 | 95.2 | 96.9 | 90.7 | 99.2 | 5.1 | 95.2 | 99.7 |
| Isolates carrying ESBL genes (145) | 82.8 | 20.0 | 15.2 | 97.9 | 74.3 | 93.8 | 97.2 | 29.0 | 97.9 |
| Isolates carrying blaCTX-M (111) | 88.3 | 23.4 | 4.5 | 98.2 | 77.3 | 95.5 | 98.2 | 22.5 | 97.3 |
| Isolates carrying blaCTX-M-15-like genes (89) | 85.4 | 9.0 | 1.1 | 97.8 | 71.6 | 94.4 | 97.8 | 25.8 | 96.6 |
| Isolates carrying blaCTX-M-14-like genes (22) | 100.0 | 81.8 | 18.2 | 100.0 | 100.0 | 100.0 | 100.0 | 9.1 | 100.0 |
| Isolates carrying blaSHV ESBL (31) | 61.3 | 6.5 | 51.6 | 96.8 | 61.3 | 87.1 | 93.5 | 54.8 | 100.0 |
| Isolates carrying blaTEM ESBL (3) | 100.0 | 33.3 | 33.3 | 100.0 | 100.0 | 100.0 | 100.0 | 0.0 | 100.0 |
| Isolates carrying blaKPC (70) | 1.4 | 0.0 | 1.4 | 2.9 | 0.0 | 54.3 | 85.3 | 8.6 | 100.0 |
| Isolates carrying transferable AmpC genes (13) | 84.6 | 7.7 | 84.6 | 100.0 | 61.5 | 100.0 | 100.0 | 53.8 | 100.0 |
a
EUCAST breakpoints were applied for colistin.
b
FDA package insert breakpoints were applied for tigecycline.